<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908360</url>
  </required_header>
  <id_info>
    <org_study_id>RC14_0372</org_study_id>
    <nct_id>NCT02908360</nct_id>
  </id_info>
  <brief_title>Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis</brief_title>
  <acronym>Prévall-DP</acronym>
  <official_title>Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of allergic diseases (atopic dermatitis, asthma, rhinitis, conjunctivitis and&#xD;
      food allergy) has increased dramatically in industrialized countries over the last 20-30&#xD;
      years.&#xD;
&#xD;
      Allergic diseases are present especially in children and young adults, but all age groups are&#xD;
      affected, with variations across countries and age. To propose new therapies, the&#xD;
      investigators must first understand the physiopathology.&#xD;
&#xD;
      Since their discovery the regulatory T cells have continued to be the subject of work to&#xD;
      understand their role in maintaining immune homeostasis in the human body but also their&#xD;
      involvement in autoimmune diseases, inflammatory diseases, transplants of solid organs or&#xD;
      fluids and allergic diseases.&#xD;
&#xD;
      It was identified two broad classes of regulatory T cells:&#xD;
&#xD;
        -  T cells = natural regulators acquisition of a phenotype and a regulatory function right&#xD;
           out of the thymus ( CD25 + / CD127 + low / FoxP3 +).&#xD;
&#xD;
        -  T cells induced regulators = acquisition of a phenotype and a regulatory function on the&#xD;
           periphery depending on the cytokine micro-environment.&#xD;
&#xD;
      Phenotypic characterization of these is less obvious and even more so than during the last&#xD;
      ten years several induced regulatory T cell populations have been described ( eg, Tr1 ).&#xD;
&#xD;
      A new subpopulation of T cells induced in patients with inflammatory bowel disease recently&#xD;
      identified have a particular phenotype as bearing the CD4 and CD8 double marking with a&#xD;
      regulatory phenotype.&#xD;
&#xD;
      These regulatory T cells are also induced a specific of a commensal intestinal bacterium&#xD;
      (Faecalibacterium prausnitzii).&#xD;
&#xD;
      Regarding allergies, it has been widely demonstrated a relationship between changes of the&#xD;
      intestinal microbiota and the occurrence of allergic diseases.&#xD;
&#xD;
      The investigators would therefore propose a cross-sectional study, single-center, controlled,&#xD;
      single blinded to study the role of T cells called double positive induced regulators DP8 to&#xD;
      compare the frequency and the regulatory function of specific DP8 of Faecalibacterium&#xD;
      prausnitzii in atopic dermatitis, asthma and allergic rhinitis compared to control samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint will be the highlight of a quantitative reduction of double positive T&#xD;
      cells (CD4 + / CD8 +) the specific F prausnitzii peripheral blood in patients with allergic&#xD;
      asthma, allergic rhinitis and atopic dermatitis compared to samples from a control sample&#xD;
      collection made available by the laboratory BIOFORTIS® located near Nantes University of&#xD;
      Nantes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>average percentage of double positive T cells CD4 + / CD8 + compared to the average percentages of total T lymphocytes (CD3 +), CD4 + and the total number of peripheral blood formed elements</measure>
    <time_frame>3 months</time_frame>
    <description>Intermediate biospecimen storage and preparation before centralized analyses</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">56</enrollment>
  <condition>Allergic Asthma</condition>
  <condition>Allergic Rhinitis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Patients with allergic rhinitis</arm_group_label>
    <description>Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with atopic dermatitis</arm_group_label>
    <description>The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD&gt; 50).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with allergic asthma</arm_group_label>
    <description>The patient has allergic asthma diagnosed according to the criteria GINA21</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse</intervention_name>
    <arm_group_label>Patients with allergic asthma</arm_group_label>
    <arm_group_label>Patients with allergic rhinitis</arm_group_label>
    <arm_group_label>Patients with atopic dermatitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing a consultation with an allergist at the University Hospital of Nantes&#xD;
        or city firm under a monitoring or an initial consultation for atopic dermatitis, allergic&#xD;
        asthma or allergic rhinitis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non smoker&#xD;
&#xD;
          -  BMI &lt;30kg/m²&#xD;
&#xD;
          -  No contraindication to prick-test&#xD;
&#xD;
          -  Inform consent signed for genetics&#xD;
&#xD;
          -  belong to a social security scheme&#xD;
&#xD;
          -  patients with allergic rhinitis or atopic dermatitis or with allergic asthma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  major or major incapable protected&#xD;
&#xD;
          -  antimicrobial treatment (antibiotic, antifungal or antiviral)&#xD;
&#xD;
          -  in contact with an MDR bacteria&#xD;
&#xD;
          -  has received or is receiving specific immunotherapy&#xD;
&#xD;
          -  History of cancer of the hematopoietic system&#xD;
&#xD;
          -  antecedent acquired immune deficiency with HIV&#xD;
&#xD;
          -  congenital immunodeficiency&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  autoimmune disease and / or inflammatory&#xD;
&#xD;
          -  solid organ transplant or hematopoietic cells&#xD;
&#xD;
          -  addict&#xD;
&#xD;
          -  pregnant or of childbearing age without effective contraception&#xD;
&#xD;
          -  failure of acute or chronic severe organ&#xD;
&#xD;
          -  hardly speak French and / or difficult to understand French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Pays De La Loire</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double positive lymphocyte T F prausnitzii</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

